jsmsJournal of Siberian Medical SciencesJournal of Siberian Medical Sciences2542-1174Federal state budgetary educational institution of higher education "Novosibirsk state medical university" of Ministry of Health of the Russian Federation (FSBEI HE NSMU MOH Russia)jsms-721Research ArticleОБЗОРЫREVIEWРак (краткий обзор)Cancer at a glanceМимунН.MimouneN.

Мимун Нура — Ph.D., H.D.R., доцент, старший преподаватель Национальной высшей школы ветеринарии; научный сотрудник лаборатории биотехнологий репродукции животных Института ветеринарии

РВ 270, г. Блида

Mimoune Nora — Ph.D., H.D.R., Senior Lecturer, Associate Professor, National High School of Veterinary Medicine; Permanent Researcher, Laboratory of Biotechnologies related to Animal Reproduction, Institute of Veterinary Sciences, University of Blida 1

РВ 270, Blida

nora.mimoune@gmail.comБахуМ. В.BahouhM. W.

Баху Мухамед Вайль — д-р ветеринарии, магистр Национальной высшей школы ветеринарии

Баб-Эззуар

Bahouh Mohamed Wail — D.V.M., M.S., National High School of Veterinary Medicine

Algeria

БукхекемС.BoukhechemS.

Букхекем Саид — Ph.D., H.D.R., доцент, старший преподаватель

Эль-Хруб

Boukhechem Said — Ph.D., H.D.R., Senior Lecturer, Associate Professor

El-Khroub, Constantine

МаруфН. У.MaroufN. O.

Маруф Нуфель Уайль — д-р ветеринарии, магистр

Баб-Эззуар

Marouf Noufel Ouail — D.V.M., M.S.

Algiers, Bab-Ezzouar

КелефД.KhelefD.

Келеф Джамель — Ph.D., H.D.R., профессор

Баб-Эззуар

Khelef Djamel — Ph.D., H.D.R., Full Professor

Algiers, Bab-Ezzouar

КаидиР.KaidiR.

Каиди Рашид — Ph.D., H.D.R., профессор

 

Kaidi Rachid — Ph.D., H.D.R., Full Professor

 

Национальная высшая школа ветеринарии; ЛБРЖ, Институт ветеринарии, Университет Блиды 1АлжирNational High School of Veterinary Medicine; LBRA, Institute of Veterinary Sciences, University of Blida 1AlgeriaНациональная высшая школа ветеринарииАлжирNational High School of Veterinary MedicineAlgeriaНациональный институт ветеринарииАлжирNational Veterinary InstituteAlgeriaЛБРЖ, Институт ветеринарии, Университет Блиды 1АлжирLBRA, Institute of Veterinary Sciences, University of Blida 1Algeria2021220820210277103Copyright © Мимун Н., Баху М.В., Букхекем С., Маруф Н.У., Келеф Д., Каиди Р., 20212021Мимун Н., Баху М.В., Букхекем С., Маруф Н.У., Келеф Д., Каиди Р.Mimoune N., Bahouh M.W., Boukhechem S., Marouf N.O., Khelef D., Kaidi R.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://jsms.elpub.ru/jour/article/view/721

Термином «рак» обозначают злокачественные опухоли различного типа. Каждый из этих типов классифицируется в зависимости от ткани, из которой развивается опухоль. Рак возникает вследствие неконтролируемого деления клеток, которые занимают место здоровых клеток. Летальность при раке, в основном, является результатом повреждений, вызванных метастазами. Вот почему крайне важно диагностировать заболевание на ранней стадии, прежде чем появятся метастазы. После постановки диагноза начинается лечение рака: оно предполагает использование различных методов, применение которых координируется на протяжении всего курса лечения. Ответ опухоли на терапию может быть различным. Одни виды рака лучше лечатся с помощью хирургических методов, другие восприимчивы к химиотерапии. Нередко для достижения наилучшего результата необходимо одновременное использование нескольких методов терапии. Исследования в области онкологии до настоящего времени в большинстве своем были посвящены раковой клетке как таковой. Актуальной задачей на современном этапе представляется понимание того, как эта клетка взаимодействует со своим ближайшим окружением. Какие процессы она приводит в действие, чтобы ускользнуть от иммунной системы, либо, напротив, успешно диссеминировать? Понимание этих механизмов может привести к созданию новых эффективных методов лечения.

Cancer is a generic term that groups different types of malignant tumors. Each of them has a specific name according to the tissue that gave birth to it. It appears when cells multiply in an uncontrolled manner and take the place of healthy cells. Deaths from cancer are mainly due to damage caused by metastases. This is why it is important to diagnose the disease early, before it spreads in the body. After the diagnosis announcement, cancer management is put in place: it involves several treatments that are articulated throughout the course of care. Cancers have the particularity of reacting differently to treatments. Some types of cancer are best treated with surgery. Others respond better to drugs called chemotherapy. It often happens that several treatments are administered together to ensure the best possible results. Studies have so far focused largely on the tumor cell itself. The new challenge for researchers is now to understand how these cells interact with their immediate environment. What processes do they put in place to escape the immune system or to successfully spread? Understanding these mechanisms could lead to the development of new types of treatment.

ракДНКгенетикаонкогенезcancerDNAgeneticoncogenesisReferencesCavenee W., White R. Anomalies génétiques et cancers // Pour la Science. 1995. Vol. 211. P. 60–68.Cavenee W., White R. (1995). Anomalies génétiques et cancers. Pour la Science, 211, 60–68.Paul S., Régulier E. Bases moléculaires de l’oncogеnèse// Ann. Biol. Clin. 2001. Vol. 59. P. 393–402.Paul S., Régulier E. (2001). Bases moléculaires de l’oncogеnèse. Ann. Biol. Clin., 59, 393–402.Favrot M.C. La cellule cancéreuse // Rev. Prat. 1997. Vol. 47. P. 1029–1036.Favrot M.C. (1997). La cellule cancéreuse. Rev. Prat., 47, 1029–1036.Diaz-Cano S.J. General morphological and biological features of neoplasms: integration of molecular findings // Histopathology. 2008. Vol. 53. P. 1–19.Diaz-Cano S.J. (2008). General morphological and biological features of neoplasms: integration of molecular findings. Histopathology, 53, 1–19.Azzouz M.Y., Mimoune N., Kaidi R. Les Tumeurs Utérines Chez la Femme, Notions Classiques et Nouvelles. Presses Académiques Francopohones, 2020.Azzouz M.Y., Mimoune N., Kaidi R. (2020). Les Tumeurs Utérines Chez la Femme, Notions Classiques et Nouvelles. Presses Académiques Francopohones.Ferlay J., Soerjomataram I., Ervik M., Dikshit R. GLOBOCAN 2012 v1.0, cancer incidence and mortality worldwide: IARC cancer base No. 11 [Internet]. International Agency for Research on Cancer. Lyon, France. 2013.Ferlay J., Soerjomataram I., Ervik M., Dikshit R. (2013). GLOBOCAN 2012 v1.0, cancer incidence and mortality worldwide: IARC cancer base No. 11 [Internet]. International Agency for Research on Cancer. Lyon, France.Scotté F., Colonna P., AndrieU J.-M. Cancérologie. Nouvelle édition. Paris: Ellipses, 2008.Scotté F., Colonna P., AndrieU J.-M. (2008). Cancérologie. Nouvelle édition. Paris: Ellipses.Davies P.C., Lineweaver C. Cancer tumors as Metazoa 1.0: tapping genes of ancient ancestors // Physical Biol. 2011. Vol. 8 (1): 015001.Davies P.C., Lineweaver C. (2011). Cancer tumors as Metazoa 1.0: tapping genes of ancient ancestors. Physic. Biol., 8 (1), 015001.National Cancer Institute. About cancer. URL: https://www.cancer.gov/about-cancer/understanding/whatis-cancer. Дата обращения: 26.03.2021.National Cancer Institute. About cancer (2015). Retrieved on March 26, 2021 from https://www.cancer.gov/about-cancer/understanding/what-is-cancer.WHO. Cancer. URL: https://www.who.int/newsroom/fact-sheets/detail/cancer. Дата обращения: 26.03.2021.WHO. Cancer (2018). Retrieved on March 26, 2021 from https://www.who.int/news-room/fact-sheets/detail/cancer.Gaspar T., Hagège D., Kevers C., Penel C. When plant teratomas turn into cancers in the absence of pathogens // Physiologia Plantarum. 1991. Vol. 83. P. 696–701.Gaspar T., Hagège D., Kevers C., Penel C. (1991). When plant teratomas turn into cancers in the absence of pathogens. Physiologia Plantarum, 83, 696–701.Doonan J., Hunt T. Why don’t plants get cancer? // Nature. 1996. Vol. 380 (6574). P. 481–482.Doonan J., Hunt T. (1996). Why don’t plants get cancer? Nature, 380 (6574), 481–482.Rothschild B.M., Tanke D.H., Helbling M. Epidemiologic study of tumors in dinosaurs // Naturwissenschaften. 2003. Vol. 90 (11). P. 495–500.Rothschild B.M., Tanke D.H., Helbling M. (2003). Epidemiologic study of tumors in dinosaurs. Naturwissenschaften, 90 (11), 495–500.Geoffrey C. The Cell: A Molecular Approach. 2nd еd., Sinauer Associates Inc., 2000.Geoffrey C. (2000). The Cell: A Molecular Approach. 2nd ed., Sinauer Associates Inc.Clarke B.B. Historical review of the causes of cancer // World J. Clin. Oncol. 2016. Vol. 7 (1). P. 54–86.Clarke B.B. (2016). Historical review of the causes of cancer. World J. Clin. Oncol., 7 (1), 54–86.Tessitore A., Cicciarelli G., Del Vecchio F. et al. MicroRNAs in the DNA damage/repair network and cancer // Int. J. Genom. 2014: 820248.Tessitore A., Cicciarelli G., Del Vecchio F. et al. (2014). MicroRNAs in the DNA damage/repair network and cancer. Int. J. Genom., 820248.Sibransky D. Emerging molecular markers of cancer // Nat. Rev. Сancer. 2002. Vol. 2 (3). P. 210–219.David S. (2002). Emerging molecular markers of cancer. Nat. Rev. Cancer, 2 (3), 210–219.Stratton M., Campbell P., Futreal P. The cancer genome // Nature. 2009. Vol. 458 (7239). P. 719–724.Stratton M., Campbell P., Futreal P. (2009). The cancer genome. Nature, 458 (7239), 719–724.Croce C.M. Oncogenes and cncer // N. Engl. J. Med. 2008. Vol. 358 (5). P. 502–511.Croce C.M. (2008). Oncogenes and cancer. N. Engl. J. Med., 358 (5), 502–511.Sarkar S., Horn G., Moulton K. et al. Cancer development, progression, and therapy: an epigenetic overview // Int. J. Mol. Sci. 2013. Vol. 14 (10). P. 21087– 21113.Sarkar S., Horn G., Moulton K. et al. (2013). Cancer development, progression, and therapy: an epigenetic overview. Int. J. Mol. Sci., 14 (10), 21087–21113.Levine A., Momand J., Finlay C. The p53 tumour suppressor gene // Nature. 1991. Vol. 351 (6326). P. 453– 456.Levine A., Momand J., Finlay C. (1991). The p53 tumour suppressor gene. Nature, 351 (6326), 453–456.Peng Y., Croce C. The role of MicroRNAs in human cancer // Sign. Transduct. Targ. Ther. 2016. Vol. 1: 15004.Peng Y., Croce C. (2016). The role of MicroRNAs in human cancer. Sign. Transduct. Targ. Ther., 1, 15004.Buder T., Deutsch A., Klink B., Voss-Böhme A. Patterns of tumor progression predict small and tissue-specifi c tumor-originating niches // Front. Oncol. 2019. Vol. 8: 668.Buder T., Deutsch A., Klink B. et al. (2019). Patterns of tumor progression predict small and tissue-specific tumor-originating niches. Front. Oncol., 8, 668.Egeblad M., Nakasone E.S., Werb Z. Tumors as organs: complex tissues that interface with the entire organism // Develop. Сell. 2010. Vol. 18 (6). P. 884–901.Egeblad M., Nakasone E.S., Werb Z. (2010). Tumors as organs: complex tissues that interface with the entire organism. Develop. Cell, 18 (6), 884–901.Siddiqui I., Sanna V., Ahmad N., Sechi M., Mukhtar H. Resveratrol nanoformulation for cancer prevention and therapy // Ann. N.Y. Acad. Sci. 2015. Vol. 1348 (1). P. 20–31.Siddiqui I., Sanna V., Ahmad N., Sechi M. (2015). Resveratrol nanoformulation for cancer prevention and therapy. Ann. N.Y. Acad. Sci., 1348 (1), 20–31.Seyfried T.N., Huysentruyt L.C. On the origin of cancer metastasis // Crit. Rev. Oncogen. 2013. Vol. 18 (1–2). P. 43–73.Seyfried T.N., Huysentruyt L.C. (2013). On the origin of cancer metastasis. Crit. Rev. Oncogen., 18 (1–2), 43–73.Qian C.-N., Mei Y., Zhang J. Cancer metastasis: issues and challenges // Chin. J. Cancer. 2017. Vol. 36 (1): 38.Qian C.-N., Mei Y., Zhang J. (2017). Cancer metastasis: issues and challenges. Chin. J. Cancer, 36 (1), 38.Fares J., Fares M.Y., Khachfe H.H., Salhab H.A., Fares Y. Molecular principles of metastasis: a hallmark of cancer revisited // Sign. Transduct. Targ. Ther. 2020. Vol. 5 (1): 28.Fares J., Fares M.Y., Khachfe H.H., Salhab H.A., Fares Y. (2020). Molecular principles of metastasis: a hall mark of cancer revisited. Sign. Transduct. Targ. Ther., 5 (1), 28.Wang R.-A., Lu Y.-Y., Fan D.-M. Reasons for cancer metastasis: A holistic perspective // Mol. Clin. Oncol. 2015. Vol. 3 (6). P. 1199–1202.Wang R.-A., Lu Y.-Y., Fan D.-M. (2015). Reasons for cancer metastasis: A holistic perspective. Mol. Clin. Oncol., 3 (6), 1199–1202.Bakhoum S.F., Ngo B., Laughney A.M. et al. Chromosomal instability drives metastasis through a cytosolic DNA response // Nature. 2018. Vol. 553 (7689). P. 467–472.Bakhoum S.F., Ngo B., Laughney A.M. et al. (2018). Chromosomal instability drives metastasis through a cytosolic DNA response. Nature, 553 (7689), 467–472.Vinay D.S., Ryan E.P., Pawelec G. et al. Immune evasion in cancer: Mechanistic basis and therapeutic strategies // Semin. Cancer Biol. 2015. Vol. 35. P. S185– S198.Vinay D.S., Ryan E.P., Pawelec G. et al. (2015). Immune evasion in cancer: Mechanistic basis and therapeutic strategies. Semin. Cancer Biol., 35, S185–S198.Gonzalez H., Hagerling C., Werb Z. Roles of the immune system in cancer: from tumor initiation to metastatic progression // Genes Dev. 2018. Vol. 32 (19–20). P. 1267–1284.Gonzalez H., Hagerling C., Werb Z. (2018). Roles of the immune system in cancer: from tumor initiation to metastatic progression. Genes Dev., 32 (19–20), 1267– 1284.Brown T. Genomes. 2nd ed. London: Oxford: WileyLiss, 2002.Brown T. (2002). Genomes. 2nd ed. London: Oxford: Wiley-Liss.Ucker D.S., Levine J.S. Exploitation of apoptotic regulation in cancer // Front. Immunol. 2018. Vol. 9: 241.Ucker D.S., Levine J.S. (2018). Exploitation of apoptotic regulation in cancer. Front. Immunol., 9, 241.National Cancer Institute. How Cancer Is Diagnosed (2019). URL: https://www.cancer.gov/about-cancer/diagnosis-staging/diagnosis. Дата обращения: 26.03.2021.National Cancer Institute. How Cancer Is Diagnosed (2019). Retrieved on March 26, 2021 from https://www.cancer.gov/about-cancer/diagnosis-staging/diagnosis.Ziv E., Durack J.C., Solomon S.B. The importance of biopsy in the era of molecular medicine // Cancer J. 2016. Vol. 22 (6). P. 418–422.Ziv E., Durack J.C., Solomon S.B. (2016). The importance of biopsy in the era of molecular medicine. Cancer J., 22 (6), 418–422.Marshall D., Laberge J.M., Firetag B., Miller T., Kerlan R.K. The changing face of percutaneous image-guided biopsy: molecular profiling and genomic analysis in current practice // J. Vasc. Interv. Radiology. 2013. Vol. 24 (8). P. 1094–1103.Marshall D., Laberge J.M., Firetag B., Miller T., Kerlan R.K. (2013). The changing face of percutaneous imageguided biopsy: molecular profiling and genomic analysis in current practice. J. Vasc. Interv. Radiology, 24 (8), 1094–1103.Palmirotta R., Lovero D., Cafforio P. et al. Liquid biopsy of cancer: a multimodal diagnostic tool in clinical oncology // Ther. Adv. Med. Oncol. 2018. Vol. 10. P. 1–24.Palmirotta R., Lovero D., Cafforio P. et al. (2018). Liquid biopsy of cancer: a multimodal diagnostic tool in clinical oncology. Ther. Adv. Med. Oncol., 10, 1–24.Alix-Panabières C. The future of liquid biopsy // Nature. 2020. Vol. 579 (7800): S9.Alix-Panabières C. (2020). The future of liquid biopsy. Nature, 579 (7800), S9.Brierley J., Gospodarowicz M., O’Sullivan B. The principles of cancer staging // еСancer. 2016. Vol. 10: ed61.Brierley J., Gospodarowicz M., O’Sullivan B. (2016). The principles of cancer staging. eCancer, 10, ed61.Arruebo M., Vilaboa N., Sáez-Gutierrez B. et al. Assessment of the evolution of cancer treatment therapies // Cancers. 2011. Vol. 3 (3). P. 3279–3330.Arruebo M., Vilaboa N., Sáez-Gutierrez B. et al. (2011). Assessment of the evolution of cancer treatment therapies. Cancers, 3 (3), 3279–3330.Falzone L., Salomone S., Libra M. Evolution of cancer pharmacological treatments at the turn of the third millennium // Front. Pharmacol. 2018. Vol. 9: 1300.Falzone L., Salomone S., Libra M. (2018). Evolution of cancer pharmacological treatments at the turn of the third millennium. Front. Pharmacol., 9, 1300.Baskar R., Lee K.A., Yeo R., Yeoh K.-W. Cancer and radiation therapy: current advances and future directions // Int. J. Med. Sci. 2012. Vol. 9 (3). P. 193–199.Baskar R., Lee K.A., Yeo R., Yeoh K.W. (2012). Cancer and radiation therapy: current advances and future directions. Int. J. Med. Sci., 9 (3), 193–199.Jaffray D.A., Gospodarowicz M. K. Radiation therapy for cancer // Cancer: Disease Control Priorities. 3rd ed. / eds. by H. Gelband et al. Washington, DC: The International Bank for Reconstruction and Development, 2015. Vol. 3.Jaffray D.A., Gospodarowicz M. K. Radiation therapy for cancer. In Gelband H. et al. (eds.) (2015). Cancer: Disease Control Priorities. 3rd ed. Washington, DC: The International Bank for Reconstruction and Development, 3.Liu M., Guo F. Recent updates on cancer immunotherapy // Prec. Clin. Med. 2018. Vol. 1 (2). Р. 65–74.Liu M., Guo F. (2018). Recent updates on cancer immunotherapy. Prec. Clin. Med., 1 (2), 65–74.Waldman A.D., Fritz J.M., Lenardo M.J. A guide to cancer immunotherapy: from T cell basic science to clinical practice // Nature Rev. Immunol. 2020. Vol. 20 (11). P. 651–668.Waldman A.D., Fritz J.M., Lenardo M.J. (2020). A guide to cancer immunotherapy: from T cell basic science to clinical practice. Nature Rev. Immunol., 20 (11), 651–668.Esfahani K., Roudaia L., Buhlaiga N. et al. A review of cancer immunotherapy: from the past, to the present, to the future // Current Oncol. 2020. Vol. 27 (2). P. S87–S97.Esfahani K., Roudaia L., Buhlaiga N. et al. (2020). A review of cancer immunotherapy: from the past, to the present, to the future. Current Oncol., 27 (2), S87–S97.Christofi T., Baritaki S., Falzone L., Libra M., Zaravinos A. Current perspectives in cancer immunotherapy // eCancer. 2019. Vol. 11 (10): 1472.Christofi T., Baritaki S., Falzone L., Libra M., Zaravinos A. (2019). Current perspectives in cancer immunotherapy. Cancers, 11 (10), 1472.Alberts B., Johnson A., Lewis J. et al. Molecular Bio logy of the Cell. 4th ed. New York: Garland Science, 2002.Alberts B., Johnson A., Lewis J. et al. (2002). Molecular Biology of the Cell. 4th ed. New York: Garland Science.Chakraborty S., Rahman T. The difficulties in cancer treatment // eCancer. 2012. Vol. 6: ed16.Chakraborty S., Rahman T. (2012). The difficulties in cancer treatment. eCancer. 6, ed16.

The authors declare that there are no conflicts of interest present.